Outcome of shorter treatment duration in non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease

被引:9
作者
Park, Yea Eun [1 ]
Chong, Yong Pil [2 ]
Kim, Ye-Jee [3 ]
Kim, Ock-Hwa [1 ]
Kwon, Byoung Soo [4 ]
Shim, Tae Sun [1 ]
Jo, Kyung-Wook [1 ]
机构
[1] Univ Ulsan, Asan Med Ctr, Coll Med, Div Pulmonol & Crit Care Med,Dept Internal Med, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
[2] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Infect Dis, Seoul, South Korea
[3] Asan Med Ctr, Dept Clin Epidemiol & Biostat, Seoul, South Korea
[4] Seoul Natl Univ, Seoul Natl Univ Bundang Hosp, Div Pulm & Crit Care Med, Dept Internal Med,Coll Med, Seongnam, South Korea
基金
新加坡国家研究基金会;
关键词
Mycobacterium avium complex (MAC); recurrence; treatment duration; culture conversion; PULMONARY-DISEASE; TUBERCULOSIS; DIAGNOSIS; IDENTIFICATION; INTRACELLULARE; VACCINATION; INFECTIONS; THERAPY; RELAPSE;
D O I
10.21037/jtd.2020.01.39
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: The recommended treatment duration for non-cavitary nodular bronchiectatic (NC-NB) Mycobacterium avium complex (MAC) lung disease (Li)) is at least 12 months after culture conversion, but evidence supporting this is limited. This study investigated whether treatment for less than 12 months after culture conversion is acceptable in terms of recurrence rate. Methods: The study enrolled the patients diagnosed with NC-NB MAC LD between 2001 and 2014 at a tertiary referral center in South Korea who received the standard treatment for at least 9 months after cul ture conversion up to October 2018. The patients were divided into a shorter treatment group (9-11 months after culture conversion) and a standard treatment group (>= 12 months). Results: Of the 228 patients enrolled, 59 (25.9%) were treated for 9-11 months after culture conversion and 169 (74.1%) for >= 12 months. The mean treatment durations after culture conversion in the shorter and standard treatment groups were 11.1 and 13.8 months, respectively (P<0.001). During median follow-up durations after the completion of treatment of 56.5 and 55.9 months, respectively, the recurrence rates in the two groups were similar, at 39.0% (23/59) and 36.7% (62/169). There were also no significant differences between the groups in the 1-year and 3-year recurrence rates. Conclusions: Post-conversion treatment shorter than the recommended duration may be adequate in terms of recurrence rate for patients with NC-NB MAC LD who receive the standard treatment for at least 9 months after culture conversion.
引用
收藏
页码:338 / 348
页数:11
相关论文
共 32 条
[1]   Relapse versus Reinfection of Mycobacterium avium Complex Pulmonary Disease Patient Characteristics and Macrolide Susceptibility [J].
Boyle, Daniel P. ;
Zembower, Teresa R. ;
Qi, Chao .
ANNALS OF THE AMERICAN THORACIC SOCIETY, 2016, 13 (11) :1956-1961
[2]   Comparison of Clinical Features, Virulence, and Relapse among Mycobacterium avium Complex Species [J].
Boyle, Daniel P. ;
Zembower, Teresa R. ;
Reddy, Susheel ;
Qi, Chao .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191 (11) :1310-1317
[3]   The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells [J].
Dartois, Veronique .
NATURE REVIEWS MICROBIOLOGY, 2014, 12 (03) :159-167
[4]   An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases [J].
Griffith, David E. ;
Aksamit, Timothy ;
Brown-Elliott, Barbara A. ;
Catanzaro, Antonino ;
Daley, Charles ;
Gordin, Fred ;
Holland, Steven M. ;
Horsburgh, Robert ;
Huitt, Gwen ;
Iademarco, Michael F. ;
Iseman, Michael ;
Olivier, Kenneth ;
Ruoss, Stephen ;
von Reyn, C. Fordham ;
Wallace, Richard J., Jr. ;
Winthrop, Kevin .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 175 (04) :367-416
[5]   British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) [J].
Haworth, Charles S. ;
Banks, John ;
Capstick, Toby ;
Fisher, Andrew J. ;
Gorsuch, Thomas ;
Laurenson, Ian F. ;
Leitch, Andrew ;
Loebinger, Michael R. ;
Milburn, Heather J. ;
Nightingale, Mark ;
Ormerod, Peter ;
Shingadia, Delane ;
Smith, David ;
Whitehead, Nuala ;
Wilson, Robert ;
Floto, R. Andres .
THORAX, 2017, 72 :ii1-ii64
[6]  
Hong YP, 1998, INT J TUBERC LUNG D, V2, P27
[7]   Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course [J].
Hwang, Ji An ;
Kim, Sunyoung ;
Jo, Kyung-Wook ;
Shim, Tae Sun .
EUROPEAN RESPIRATORY JOURNAL, 2017, 49 (03)
[8]   Adverse reactions associated with long-term drug administration in Mycobacterium avium complex lung disease [J].
Kamii, Y. ;
Nagai, H. ;
Kawashima, M. ;
Matsuki, M. ;
Nagoshi, S. ;
Sato, A. ;
Kohno, S. ;
Ohgiya, M. ;
Ohta, K. .
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2018, 22 (12) :1505-+
[9]   Association Between Duration of Aminoglycoside Treatment and Outcome of Cavitary Mycobacterium avium Complex Lung Disease [J].
Kim, Ock-Hwa ;
Kwon, Byoung Soo ;
Han, Minkyu ;
Koh, Younsuck ;
Kim, Woo-Sung ;
Song, Jin-Woo ;
Oh, Yeon-Mok ;
Lee, Sang-Do ;
Lee, Sei Won ;
Lee, Jae-Seung ;
Lim, Chae-Man ;
Choi, Chang-Min ;
Huh, Jin-Won ;
Hong, Sang-Bum ;
Shim, Tae Sun ;
Jo, Kyung-Wook .
CLINICAL INFECTIOUS DISEASES, 2019, 68 (11) :1870-1876
[10]   Changing Epidemiology of Nontuberculous Mycobacterial Lung Diseases in a Tertiary Referral Hospital in Korea between 2001 and 2015 [J].
Ko, Ryoung-Eun ;
Moon, Seong Mi ;
Ahn, Soohyun ;
Jhun, Byung Woo ;
Jeon, Kyeongman ;
Kwon, O. Jung ;
Huh, Hee Jae ;
Ki, Chang-Seok ;
Lee, Nam Yong ;
Koh, Won-Jung .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2018, 33 (08)